Michael S Benjamin, MD
Hematology/Oncology · West Hills
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 28 years
- Tulane University School of Medicine, 1998
Offices
3 locations
Hospitals listed: Adventist Health Simi Valley · Los Robles Hospital & Medical Center · UCLA West Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Benjamin’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A86460 · Current
Licensed to practise in California · since 2004 · expires 2028-01-31 · Tulane University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Simi ValleySimi Valley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 3.418, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.159, Oct 2024 – Sep 2025
- Los Robles Hospital & Medical CenterThousand Oaks, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- UCLA West Valley Medical CenterWest Hills, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 1 of 5 · 53% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.454, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Simi Valley
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 3.418 | Worse | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.159 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 722 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.69 to 1.48) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.92 (137.46 to 254.38) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 128 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.4 · 128 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 469 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 164 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 1,835 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,577 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 4,587 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.64 (2.34 to 6.95) · 698 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.1 (0.39 to 3.82) · 147 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.04 to 4.31) · 675 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.9 (3.52 to 22.28) · 145 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.67 (2.48 to 10.87) · 139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 162 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.04) · 3,793 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 2.753 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 146 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.5 · 450 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.5 · 131 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.8 · 349 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 29.1 · 490 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.4 · 531 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 75 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.5 to 18.7) · 353 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 157 cases | No different | Jan 2024 – Dec 2024 |
What patients said (486 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 82% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 68% |
| Doctors "always" treated them with courtesy and respect | 77% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Los Robles Hospital & Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.84 (0 to 1.7) · 2,135 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.56 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 194.58 (150.2 to 238.96) · 162 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 76 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.3 · 251 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 535 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 970 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 352 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,468 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.33) · 12,215 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.03 to 0.38) · 12,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3 (1.28 to 4.71) · 3,156 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.29 (0 to 2.81) · 1,553 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.74 (0.42 to 3.07) · 3,078 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.59 (6.22 to 16.96) · 1,658 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.29 (2.13 to 8.45) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.51 (0.09 to 2.92) · 825 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.1 (0 to 0.64) · 9,549 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 208 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.763 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.621 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.855 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.744 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 239 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 502 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.9 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -7.5 · 623 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31 · 1,042 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 939 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 197 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.3 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 213 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.7 to 17) · 361 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 718 cases | No different | Jan 2024 – Dec 2024 |
What patients said (682 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 65% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for UCLA West Valley Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.454 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.87 (0 to 1.86) · 925 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.74 to 1.41) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 126.11 (75.24 to 176.99) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 179 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 310 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.3 · 499 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 187 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.36) · 5,783 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.09 to 0.48) · 5,787 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.94 (1.81 to 6.06) · 1,083 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.83 (0.29 to 3.36) · 1,048 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.62 (6.73 to 22.51) · 354 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 319 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 221 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1.09) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.457 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.124 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.781 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.838 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 201 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 400 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.5 · 173 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.2 · 369 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 51.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 569 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.8 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (9.3 to 17.4) · 30 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 136 cases | No different | Jan 2024 – Dec 2024 |
What patients said (519 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 67% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 64% |
| Doctors "always" treated them with courtesy and respect | 73% |
| Patients who gave a rating of "9" or "10" (high) | 52% |
| Staff "always" explained new medications | 64% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 74% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 53% |
| Staff "always" explained possible side effects | 35% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
Original Medicare doctor bills
$2,056,789
Medicare paid this office $2,056,789 for 401 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 285 | $98,587 | $74 |
| Injection, denosumab, 1 mg | 22 | $57,146 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $44,160 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $24,176 | $97 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $23,061 | $117 |
See all 25 services
| Short return visit (20+ min) | 285 | $98,587 | $74 |
| Injection, denosumab, 1 mg | 22 | $57,146 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $44,160 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $24,176 | $97 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $23,061 | $117 |
| Injection, ferric carboxymaltose, 1 mg | 16 | $20,027 | None |
| Return visit (30+ min) | 108 | $15,857 | $97 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 58 | $14,326 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $13,189 | $25 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $9,655 | $142 |
| Injection of drug or substance under skin or into muscle | 107 | $8,948 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 61 | $8,864 | $18 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $5,962 | $66 |
| Long return visit (40+ min) | 28 | $5,386 | $146 |
| New patient visit (45+ min) | 36 | $5,058 | $140 |
| Injection of additional new drug or substance into vein | 41 | $3,158 | $14 |
| Administration of chemotherapy into vein, each additional hour | 23 | $3,041 | $25 |
| Short return visit | 36 | $1,601 | $42 |
| Injection, granisetron hydrochloride, 100 mcg | 31 | $435 | None |
| Insertion of needle into vein (3 years or older) | 28 | $371 | $10 |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $238 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 38 | $144 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | $56 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $44 | None |
| Unclassified drugs | 11 | $8 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of needle into vein (3 years or older) | – | – | – | – | 137 | 38 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
401 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 18% · Women 62% · Also on Medicaid 44% · Health risk score 1.97. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 48% · Coronary heart disease 45% · Cancer 45% · Chronic kidney disease 34% · Heart failure 32% · Depression 32% · Atrial fibrillation 26% · COPD 21% · Dementia 15% · Stroke 12%.
The office billed $4,630,861, Medicare allowed $2,594,789 and paid $2,056,789; for 79,034 services of 90 kinds; $1,806,984 of it was for drugs given in the office and $249,805 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 401 | 79,034 | 75 | 1.97 | $4,630,861 | $2,056,789 |
| 2023 | 499 | 103,503 | 75 | 1.86 | $5,923,894 | $2,462,519 |
| 2022 | 504 | 88,518 | 75 | 2.02 | $4,115,950 | $1,729,254 |
| 2021 | 475 | 90,154 | 74 | 1.90 | $4,114,660 | $1,828,654 |
| 2020 | 454 | 105,900 | 74 | 2.37 | $3,766,340 | $1,641,734 |
| 2019 | 465 | 116,077 | 74 | 2.58 | $3,822,354 | $1,604,906 |
| 2018 | 584 | 115,911 | 75 | 2.32 | $4,185,642 | $1,587,168 |
| 2017 | 350 | 44,422 | 75 | 2.02 | $2,071,925 | $847,330 |
| 2016 | 273 | 37,030 | 75 | 2.00 | $1,461,003 | $539,553 |
| 2015 | 264 | 61,991 | 74 | 1.97 | $1,720,877 | $686,811 |
| 2014 | 246 | 95,235 | 74 | 1.99 | $1,138,324 | $426,648 |
| 2013 | 240 | 23,239 | 74 | 1.97 | $1,101,628 | $414,970 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 27 services
| Short return visit (20+ min) | 283 | $90,007 | $74 |
| Injection, denosumab, 1 mg | 23 | $73,293 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 94 | $45,660 | $99 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 20 | $45,170 | None |
| Return visit (30+ min) | 153 | $30,714 | $103 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $30,233 | $119 |
| Injection, ferric carboxymaltose, 1 mg | 22 | $22,473 | None |
| Long return visit (40+ min) | 81 | $22,069 | $146 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $19,328 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 79 | $17,550 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $12,864 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 80 | $12,247 | $18 |
| Injection of drug or substance under skin or into muscle | 124 | $10,424 | $12 |
| Short return visit | 93 | $6,680 | $46 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $6,301 | $66 |
| New patient visit (60+ min) | 33 | $6,096 | $185 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $4,849 | $59 |
| Injection of additional new drug or substance into vein | 47 | $4,652 | $14 |
| Administration of chemotherapy into vein, each additional hour | 27 | $4,230 | $25 |
| New patient visit (30+ min) | 45 | $3,899 | $87 |
| New patient visit (45+ min) | 30 | $3,627 | $121 |
| Insertion of needle into vein (3 years or older) | 56 | $2,054 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $802 | $28 |
| Injection, granisetron hydrochloride, 100 mcg | 35 | $737 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 38 | $262 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $210 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 63 | $153 | None |
2022: 28 services
| Short return visit (20+ min) | 332 | $93,039 | $73 |
| Injection, denosumab, 1 mg | 20 | $58,962 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 27 | $56,948 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 103 | $53,452 | $86 |
| Short return visit | 224 | $37,230 | $47 |
| Return visit (30+ min) | 149 | $33,988 | $106 |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $33,760 | $126 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 49 | $20,448 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 68 | $18,040 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $17,397 | $166 |
| Long return visit (40+ min) | 53 | $12,468 | $154 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 76 | $10,706 | $19 |
| Injection of drug or substance under skin or into muscle | 118 | $9,954 | $12 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $5,739 | $70 |
| New patient visit (30+ min) | 59 | $5,437 | $92 |
| New patient visit (60+ min) | 29 | $5,366 | $185 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $5,337 | $62 |
| Administration of chemotherapy into vein, each additional hour | 31 | $4,646 | $27 |
| New patient visit (45+ min) | 34 | $4,565 | $134 |
| Injection of additional new drug or substance into vein | 49 | $4,297 | $15 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 34 | $1,036 | $20 |
| Injection of drug or substance into vein | 13 | $1,022 | $35 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $919 | $30 |
| Injection, granisetron hydrochloride, 100 mcg | 43 | $692 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 81 | $341 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 41 | $247 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 41 | $221 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $38 | None |
2021: 29 services
| Short return visit (20+ min) | 341 | $95,784 | $74 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 23 | $60,555 | None |
| Injection, denosumab, 1 mg | 20 | $54,024 | None |
| Short return visit | 216 | $45,501 | $47 |
| Administration of chemotherapy into vein, 1 hour or less | 45 | $40,370 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $36,172 | $88 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 56 | $26,860 | $29 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 60 | $25,676 | $66 |
| Return visit (30+ min) | 93 | $18,390 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $14,727 | $169 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 83 | $13,250 | $20 |
| Injection of drug or substance under skin or into muscle | 111 | $9,855 | $12 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $7,300 | $66 |
| New patient visit (30+ min) | 74 | $6,683 | $90 |
| Administration of chemotherapy into vein, each additional hour | 35 | $6,464 | $29 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $6,386 | $75 |
| New patient visit (45+ min) | 37 | $5,183 | $140 |
| Injection of additional new drug or substance into vein | 54 | $4,600 | $16 |
| New patient visit (60+ min) | 24 | $4,551 | $190 |
| Injection, iron sucrose, 1 mg | 23 | $3,530 | None |
| Long return visit (40+ min) | 17 | $3,159 | $158 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 62 | $2,120 | $19 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | $1,946 | $61 |
| Injection of drug or substance into vein | 13 | $1,155 | $37 |
| Injection, granisetron hydrochloride, 100 mcg | 46 | $614 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 92 | $532 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 46 | $315 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 47 | $190 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $56 | None |
2020: 30 services
| Short return visit (20+ min) | 281 | $58,803 | $59 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 26 | $54,689 | None |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $41,856 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $35,004 | $90 |
| Short return visit | 197 | $33,441 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $28,790 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | $26,816 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 101 | $20,723 | $174 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 83 | $15,855 | $20 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $12,472 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $9,395 | $63 |
| Return visit (30+ min) | 66 | $8,529 | $86 |
| Administration of chemotherapy into vein, each additional hour | 29 | $7,480 | $28 |
| Injection of drug or substance under skin or into muscle | 92 | $7,429 | $12 |
| New patient visit (45+ min) | 46 | $6,345 | $138 |
| Injection of additional new drug or substance into vein | 50 | $5,163 | $15 |
| Injection, iron sucrose, 1 mg | 37 | $4,220 | None |
| New patient visit (30+ min) | 38 | $3,492 | $92 |
| New patient visit (60+ min) | 19 | $3,435 | $181 |
| Long return visit (40+ min) | 18 | $2,880 | $125 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $2,261 | $66 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 53 | $2,074 | $20 |
| Injection, ranitidine hydrochloride, 25 mg | 37 | $1,269 | None |
| Injection, granisetron hydrochloride, 100 mcg | 40 | $655 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 92 | $593 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $530 | None |
| Injection, carboplatin, 50 mg | 11 | $482 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $186 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $62 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $36 | None |
2019: 30 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 23 | $88,124 | None |
| Short return visit (20+ min) | 296 | $71,540 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $45,022 | $89 |
| Administration of chemotherapy into vein, 1 hour or less | 46 | $43,893 | $129 |
| Short return visit | 162 | $31,244 | $39 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 56 | $27,561 | $29 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 125 | $25,203 | $173 |
| Return visit (30+ min) | 122 | $20,815 | $92 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 56 | $19,545 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 97 | $13,950 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $13,929 | $62 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $12,680 | $63 |
| Injection of drug or substance under skin or into muscle | 95 | $10,586 | $15 |
| Administration of chemotherapy into vein, each additional hour | 35 | $6,823 | $28 |
| Injection of additional new drug or substance into vein | 57 | $5,110 | $15 |
| Long return visit (40+ min) | 24 | $5,096 | $127 |
| Injection, iron sucrose, 1 mg | 35 | $4,761 | None |
| New patient visit (45+ min) | 27 | $3,864 | $143 |
| New patient visit (60+ min) | 20 | $3,579 | $179 |
| New patient visit (30+ min) | 41 | $3,557 | $87 |
| Injection, ranitidine hydrochloride, 25 mg | 50 | $1,585 | None |
| Injection of drug or substance into vein | 15 | $1,079 | $35 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $992 | $28 |
| Injection, granisetron hydrochloride, 100 mcg | 51 | $953 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $951 | $20 |
| Injection, carboplatin, 50 mg | 12 | $607 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 50 | $563 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 100 | $508 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 52 | $185 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $44 | None |
2018: 33 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 141 | $74,368 | $86 |
| Short return visit (20+ min) | 317 | $69,257 | $56 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 17 | $44,190 | None |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $38,472 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 183 | $37,312 | $166 |
| Short return visit | 134 | $27,154 | $36 |
| Return visit (30+ min) | 161 | $24,688 | $84 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 55 | $24,491 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $16,829 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 49 | $16,745 | $64 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $14,311 | $71 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 85 | $12,687 | $19 |
| Injection of drug or substance under skin or into muscle | 98 | $10,548 | $17 |
| Administration of additional new drug or substance into vein, 1 hour or less | 24 | $5,238 | $61 |
| New patient visit (45+ min) | 37 | $5,029 | $136 |
| Injection of additional new drug or substance into vein | 56 | $4,990 | $16 |
| New patient visit (30+ min) | 56 | $4,773 | $85 |
| Administration of chemotherapy into vein, each additional hour | 35 | $4,518 | $27 |
| Long return visit (40+ min) | 22 | $4,408 | $119 |
| New patient visit (60+ min) | 26 | $3,926 | $151 |
| Injection, iron sucrose, 1 mg | 22 | $3,592 | None |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,663 | $41 |
| Injection, ranitidine hydrochloride, 25 mg | 51 | $1,583 | None |
| Injection of drug or substance into vein | 16 | $1,338 | $41 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $1,000 | $19 |
| Injection, granisetron hydrochloride, 100 mcg | 51 | $765 | None |
| Injection, carboplatin, 50 mg | 13 | $754 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $592 | $12 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 91 | $588 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 52 | $553 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 51 | $140 | None |
| Insertion of needle into vein for collection of blood sample | 15 | $62 | $3 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $31 | None |
2017: 22 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $57,048 | None |
| Short return visit (20+ min) | 221 | $47,150 | $57 |
| Administration of chemotherapy into vein, 1 hour or less | 24 | $18,564 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $18,294 | $88 |
| Short return visit | 83 | $17,038 | $37 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $15,492 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $12,855 | $171 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $9,463 | $61 |
| Injection of drug or substance under skin or into muscle | 59 | $7,222 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $7,084 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 45 | $5,748 | $16 |
| Return visit (30+ min) | 46 | $4,507 | $83 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $2,392 | $58 |
| New patient visit (30+ min) | 28 | $2,347 | $84 |
| Injection of additional new drug or substance into vein | 28 | $2,235 | $20 |
| Administration of chemotherapy into vein, each additional hour | 19 | $1,967 | $25 |
| Injection of drug or substance into vein | 11 | $836 | $49 |
| Injection, ranitidine hydrochloride, 25 mg | 26 | $363 | None |
| Injection, granisetron hydrochloride, 100 mcg | 28 | $322 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 49 | $234 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $153 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 29 | $57 | None |
2016: 21 services
| Short return visit (20+ min) | 199 | $58,603 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 69 | $28,576 | $61 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $27,743 | None |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $19,976 | $122 |
| Short return visit | 57 | $10,143 | $37 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $9,266 | $172 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $6,779 | $61 |
| Injection of drug or substance under skin or into muscle | 48 | $6,285 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 35 | $5,448 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 23 | $4,282 | $27 |
| Return visit (30+ min) | 44 | $4,209 | $79 |
| New patient visit (30+ min) | 38 | $3,171 | $83 |
| Injection of additional new drug or substance into vein | 25 | $2,986 | $20 |
| Administration of chemotherapy into vein, each additional hour | 18 | $2,532 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 11 | $2,201 | $56 |
| Injection, granisetron hydrochloride, 100 mcg | 22 | $367 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $282 | $17 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 41 | $227 | None |
| Injection, ranitidine hydrochloride, 25 mg | 22 | $224 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 23 | $144 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $58 | None |
2015: 22 services
| Short return visit (20+ min) | 156 | $55,473 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $21,166 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | $13,522 | $120 |
| Return visit (30+ min) | 90 | $10,708 | $78 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $10,571 | $168 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $9,219 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 18 | $8,245 | $27 |
| Short return visit | 47 | $7,009 | $36 |
| Injection of drug or substance under skin or into muscle | 39 | $6,384 | $22 |
| New patient visit (60+ min) | 34 | $5,908 | $174 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 33 | $5,041 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,926 | $85 |
| Injection of additional new drug or substance into vein | 23 | $3,335 | $20 |
| Administration of chemotherapy into vein, each additional hour | 14 | $2,877 | $25 |
| Injection, iron sucrose, 1 mg | 13 | $1,973 | None |
| Injection of drug or substance into vein | 22 | $1,866 | $48 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $467 | $17 |
| Injection, granisetron hydrochloride, 100 mcg | 15 | $436 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $222 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 33 | $220 | None |
| Injection, ranitidine hydrochloride, 25 mg | 15 | $185 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $51 | None |
2014: 21 services
| Return visit (30+ min) | 176 | $73,829 | $84 |
| Short return visit (20+ min) | 81 | $18,271 | $60 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $16,189 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $14,477 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $12,919 | $166 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $11,989 | $26 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $7,851 | $64 |
| Short return visit | 37 | $7,334 | $36 |
| New patient visit (60+ min) | 41 | $6,429 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 21 | $5,118 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 32 | $4,325 | $16 |
| Injection of drug or substance under skin or into muscle | 26 | $3,834 | $22 |
| Injection of additional new drug or substance into vein | 16 | $3,753 | $19 |
| Injection of drug or substance into vein | 27 | $3,001 | $49 |
| Administration of chemotherapy into vein, each additional hour | 11 | $2,608 | $24 |
| Long return visit (40+ min) | 17 | $2,269 | $113 |
| Injection, granisetron hydrochloride, 100 mcg | 13 | $466 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $308 | None |
| Injection, ranitidine hydrochloride, 25 mg | 13 | $270 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 36 | $199 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $68 | None |
2013: 20 services
| Return visit (30+ min) | 148 | $81,177 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 78 | $28,758 | $58 |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $23,563 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 84 | $16,436 | $163 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 21 | $11,985 | $28 |
| Short return visit (20+ min) | 52 | $7,740 | $59 |
| New patient visit (60+ min) | 45 | $7,247 | $161 |
| Injection of additional new drug or substance into vein | 22 | $5,271 | $20 |
| Long return visit (40+ min) | 40 | $5,193 | $108 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $4,600 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $4,139 | $19 |
| Injection of drug or substance into vein | 20 | $3,540 | $47 |
| Short return visit | 26 | $3,326 | $36 |
| Administration of chemotherapy into vein, each additional hour | 13 | $1,254 | $27 |
| Injection, granisetron hydrochloride, 100 mcg | 15 | $560 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $475 | $16 |
| Injection, ranitidine hydrochloride, 25 mg | 15 | $249 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $218 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 31 | $146 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $72 | None |
Medicaid work
$6,181 in 2024
Medicaid paid $6,181 for 485 billed services this clinician did in 2024, up to 33 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 327 | $4,546 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 124 | $1,045 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 18 | $590 |
| New patient visit (45+ min) | 16 | $0 |
| 2024 | 485 | 4 | 33 | $6,181 |
| 2023 | 406 | 3 | 29 | $13,140 |
| 2022 | 484 | 4 | 27 | $36,339 |
| 2021 | 224 | 2 | 20 | $6,735 |
| 2020 | 494 | 5 | 41 | $23,742 |
| 2019 | 1,162 | 7 | 43 | $39,222 |
| 2018 | 1,498 | 9 | 39 | $11,637 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 306 | $10,917 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 83 | $1,917 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 17 | $306 |
2022
| Short return visit (20+ min) | 281 | $30,207 |
| Short return visit | 129 | $4,500 |
| Return visit (30+ min) | 13 | $1,276 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 61 | $356 |
2021
| Short return visit (20+ min) | 138 | $4,810 |
| Short return visit | 86 | $1,924 |
2020
| Short return visit (20+ min) | 258 | $13,130 |
| Short return visit | 92 | $6,944 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 68 | $1,957 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 61 | $944 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 15 | $767 |
2019
| Short return visit (20+ min) | 452 | $11,859 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 311 | $10,920 |
| Short return visit | 130 | $8,634 |
| 1ST HOSP IP/OBS HIGH 75 | 59 | $3,840 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 73 | $2,835 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 98 | $1,104 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 39 | $30 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 117 | $3,156 |
| Short return visit (20+ min) | 551 | $2,393 |
| 1ST HOSP IP/OBS HIGH 75 | 50 | $1,945 |
| Return visit (30+ min) | 65 | $1,516 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 156 | $851 |
| Short return visit | 129 | $801 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) | 274 | $512 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 61 | $459 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 95 | $6 |
Drugs they prescribed that Part D paid
$12,314,939
Pharmacies billed $12,314,939 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
296 generic and 1,539 brand-name prescriptions · $12,314,939 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 242 | $3,217,887 | $13,297 |
| Procrit | 502 | $2,709,605 | $5,398 |
| Neulasta | 126 | $934,301 | $7,415 |
| Imbruvica | 40 | $627,484 | $15,687 |
| Calquence | 41 | $624,950 | $15,243 |
See all 32 drugs
| Xtandi | None | 242 | $3,217,887 | $13,297 |
| Procrit | None | 502 | $2,709,605 | $5,398 |
| Neulasta | None | 126 | $934,301 | $7,415 |
| Imbruvica | None | 40 | $627,484 | $15,687 |
| Calquence | None | 41 | $624,950 | $15,243 |
| Gammagard Liquid | Immune globulin | 63 | $403,023 | $6,397 |
| Lupron Depot | None | 72 | $377,434 | $5,242 |
| Kisqali | None | 22 | $325,679 | $14,804 |
| Xgeva | None | 94 | $278,341 | $2,961 |
| Erleada | None | 17 | $247,748 | $14,573 |
| Tagrisso | None | 14 | $237,928 | $16,995 |
| Ibrance | None | 14 | $217,499 | $15,536 |
| Nplate | None | 20 | $186,910 | $9,346 |
| Ninlaro | None | 14 | $185,265 | $13,233 |
| Darzalex Faspro | None | 13 | $171,522 | $13,194 |
| Tysabri | None | 14 | $102,807 | $7,343 |
| Privigen | Immune globulin | 15 | $95,966 | $6,398 |
| Lynparza | None | 13 | $95,804 | $7,370 |
| Gamunex-C | Immune globulin | 12 | $89,523 | $7,460 |
| Octagam | Immune globulin | 13 | $89,333 | $6,872 |
| Ruxience | None | 11 | $55,478 | $5,043 |
| Fondaparinux | None | 19 | $36,204 | $1,905 |
| Imatinib Mesylate | None | 30 | $26,554 | $885 |
| Retacrit | None | 12 | $20,719 | $1,727 |
| Xarelto | None | 20 | $17,595 | $880 |
| Eliquis | None | 23 | $16,609 | $722 |
| Fulvestrant | None | 35 | $13,954 | $399 |
| Anastrozole | None | 36 | $491 | $14 |
| Hydroxyurea | None | 21 | $345 | $16 |
| Ondansetron | None | 25 | $298 | $12 |
| Carboplatin | None | 12 | $285 | $24 |
| Ondansetron Odt | None | 17 | $273 | $16 |
Year by year
| 2024 | 1,835 | 225 | None | 84% | $12,314,939 |
| 2023 | 1,255 | 142 | None | 85% | $9,727,667 |
| 2022 | 1,558 | 173 | 1% (18) | 82% | $10,379,603 |
| 2021 | 1,968 | 169 | 1% (21) | 84% | $13,695,328 |
| 2020 | 1,885 | 150 | 1% (21) | 82% | $13,441,494 |
| 2019 | 1,764 | 162 | 1% (17) | 84% | $11,150,629 |
| 2018 | 1,942 | 180 | 3% (60) | 76% | $10,536,776 |
| 2017 | 1,428 | 182 | 3% (36) | 71% | $6,682,485 |
| 2016 | 1,275 | 148 | 2% (30) | 58% | $4,624,126 |
| 2015 | 1,227 | 166 | 6% (69) | 59% | $3,929,598 |
| 2014 | 1,292 | 156 | 6% (73) | 50% | $2,938,836 |
| 2013 | 1,112 | 123 | 8% (91) | None | $1,652,164 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Procrit | None | 305 | $2,059,526 | $6,753 |
| Xtandi | None | 106 | $1,580,724 | $14,912 |
| Neulasta | None | 101 | $780,415 | $7,727 |
| Imbruvica | None | 43 | $703,298 | $16,356 |
| Gammagard Liquid | Immune globulin | 74 | $496,026 | $6,703 |
| Kisqali | None | 19 | $317,398 | $16,705 |
| Calquence | None | 15 | $234,584 | $15,639 |
| Lupron Depot | None | 38 | $234,045 | $6,159 |
| Sprycel | None | 12 | $228,187 | $19,016 |
| Xgeva | None | 72 | $221,601 | $3,078 |
| Ibrance | None | 14 | $220,965 | $15,783 |
| Hizentra | Immune globulin | 22 | $209,246 | $9,511 |
| Tagrisso | None | 12 | $206,792 | $17,233 |
| Ninlaro | None | 13 | $178,112 | $13,701 |
| Venclexta | None | 11 | $165,462 | $15,042 |
| Tecentriq | None | 12 | $117,752 | $9,813 |
| Tysabri | None | 11 | $107,361 | $9,760 |
| Zarxio | None | 11 | $91,597 | $8,327 |
| Imatinib Mesylate | None | 18 | $85,094 | $4,727 |
| Rituxan | None | 11 | $76,119 | $6,920 |
| Ruxience | None | 14 | $72,998 | $5,214 |
| Privigen | Immune globulin | 13 | $69,251 | $5,327 |
| Fondaparinux | None | 15 | $39,189 | $2,613 |
| Xarelto | None | 20 | $15,447 | $772 |
| Fulvestrant | None | 27 | $15,179 | $562 |
| Eliquis | None | 22 | $15,132 | $688 |
| Hydroxyurea | None | 12 | $547 | $46 |
| Anastrozole | None | 20 | $504 | $25 |
| Ondansetron | None | 23 | $423 | $18 |
2022: 30 drugs
| Procrit | None | 445 | $2,696,473 | $6,059 |
| Imbruvica | None | 66 | $1,034,679 | $15,677 |
| Neulasta | None | 125 | $957,509 | $7,660 |
| Xtandi | None | 61 | $828,461 | $13,581 |
| Gammagard Liquid | Immune globulin | 110 | $708,510 | $6,441 |
| Ibrance | None | 29 | $407,859 | $14,064 |
| Ninlaro | None | 27 | $329,163 | $12,191 |
| Hizentra | Immune globulin | 33 | $279,216 | $8,461 |
| Imatinib Mesylate | None | 34 | $263,451 | $7,749 |
| Tagrisso | None | 13 | $215,551 | $16,581 |
| Xgeva | None | 77 | $214,966 | $2,792 |
| Lupron Depot | None | 40 | $205,916 | $5,148 |
| Venclexta | None | 14 | $194,432 | $13,888 |
| Tecentriq | None | 19 | $182,007 | $9,579 |
| Rituxan | None | 21 | $180,736 | $8,606 |
| Zarxio | None | 13 | $166,730 | $12,825 |
| Nplate | None | 13 | $129,727 | $9,979 |
| Tysabri | None | 13 | $116,920 | $8,994 |
| Gammagard S-D | Immune globulin | 14 | $112,936 | $8,067 |
| Privigen | Immune globulin | 14 | $68,501 | $4,893 |
| Octagam | Immune globulin | 11 | $59,956 | $5,451 |
| Fondaparinux | None | 20 | $45,652 | $2,283 |
| Azacitidine | None | 14 | $29,143 | $2,082 |
| Fulvestrant | None | 20 | $16,286 | $814 |
| Eliquis | None | 19 | $13,724 | $722 |
| Xarelto | None | 12 | $11,146 | $929 |
| Hydroxyurea | None | 28 | $1,360 | $49 |
| Hydrocodone-Acetaminophen | None | 13 | $476 | $37 |
| Anastrozole | None | 23 | $411 | $18 |
| Ondansetron | None | 28 | $379 | $14 |
2021: 41 drugs
| Procrit | None | 387 | $2,355,381 | $6,086 |
| Xtandi | None | 114 | $1,469,087 | $12,887 |
| Imbruvica | None | 96 | $1,468,353 | $15,295 |
| Neulasta | None | 134 | $1,001,611 | $7,475 |
| Gammagard Liquid | Immune globulin | 150 | $911,702 | $6,078 |
| Zarxio | None | 67 | $766,167 | $11,435 |
| Promacta | None | 21 | $463,971 | $22,094 |
| Ibrance | None | 31 | $401,400 | $12,948 |
| Jakafi | None | 27 | $372,192 | $13,785 |
| Ninlaro | None | 26 | $296,877 | $11,418 |
| Lupron Depot | None | 63 | $219,992 | $3,492 |
| Hizentra | Immune globulin | 29 | $219,023 | $7,553 |
| Rubraca | None | 12 | $218,004 | $18,167 |
| Xgeva | None | 84 | $212,149 | $2,526 |
| Tagrisso | None | 13 | $211,165 | $16,243 |
| Keytruda | None | 20 | $209,274 | $10,464 |
| Rituxan | None | 23 | $203,607 | $8,852 |
| Octagam | Immune globulin | 18 | $157,723 | $8,762 |
| Nplate | None | 17 | $142,796 | $8,400 |
| Tecentriq | None | 15 | $138,163 | $9,211 |
| Gammagard S-D | Immune globulin | 16 | $122,300 | $7,644 |
| Lynparza | None | 12 | $119,456 | $9,955 |
| Tysabri | None | 14 | $116,905 | $8,350 |
| Gamunex-C | Immune globulin | 18 | $97,749 | $5,431 |
| Perjeta | None | 14 | $87,100 | $6,221 |
| Imfinzi | None | 12 | $74,683 | $6,224 |
| Azacitidine | None | 20 | $69,270 | $3,463 |
| Herceptin | None | 14 | $68,726 | $4,909 |
| Imatinib Mesylate | None | 11 | $68,672 | $6,243 |
| Fondaparinux | None | 15 | $32,412 | $2,161 |
| Fulvestrant | None | 24 | $29,510 | $1,230 |
| Eliquis | None | 42 | $25,387 | $604 |
| Retacrit | None | 13 | $23,469 | $1,805 |
| Sancuso | None | 18 | $22,920 | $1,273 |
| Xarelto | None | 15 | $16,161 | $1,077 |
| Anastrozole | None | 48 | $1,149 | $24 |
| Gemcitabine | None | 13 | $1,071 | $82 |
| Hydroxyurea | None | 26 | $817 | $31 |
| Hydrocodone-Acetaminophen | None | 15 | $491 | $33 |
| Ondansetron | None | 25 | $354 | $14 |
| Metoclopramide | None | 11 | $157 | $14 |
2020: 37 drugs
| Procrit | None | 401 | $2,244,698 | $5,598 |
| Neulasta | None | 172 | $1,367,210 | $7,949 |
| Xtandi | None | 84 | $1,101,260 | $13,110 |
| Imbruvica | None | 80 | $1,055,301 | $13,191 |
| Soliris | None | 16 | $876,269 | $54,767 |
| Promacta | None | 27 | $585,098 | $21,670 |
| Ninlaro | None | 51 | $545,992 | $10,706 |
| Gammagard Liquid | Immune globulin | 94 | $542,515 | $5,771 |
| Zarxio | None | 40 | $470,994 | $11,775 |
| Ibrance | None | 38 | $463,454 | $12,196 |
| Revlimid | None | 25 | $413,995 | $16,560 |
| Imatinib Mesylate | None | 23 | $346,610 | $15,070 |
| Jakafi | None | 19 | $235,326 | $12,386 |
| Lynparza | None | 17 | $226,670 | $13,334 |
| Xgeva | None | 96 | $223,158 | $2,325 |
| Gamunex-C | Immune globulin | 47 | $221,020 | $4,703 |
| Neulasta Onpro | None | 20 | $208,277 | $10,414 |
| Tagrisso | None | 12 | $190,527 | $15,877 |
| Lupron Depot | None | 38 | $159,134 | $4,188 |
| Avastin | None | 16 | $147,275 | $9,205 |
| Rituxan | None | 18 | $126,871 | $7,048 |
| Tysabri | None | 16 | $121,431 | $7,589 |
| Hizentra | Immune globulin | 20 | $119,741 | $5,987 |
| Gammagard S-D | Immune globulin | 15 | $111,297 | $7,420 |
| Tecentriq | None | 12 | $107,576 | $8,965 |
| Azacitidine | None | 12 | $69,156 | $5,763 |
| Faslodex | None | 16 | $29,781 | $1,861 |
| Fondaparinux | None | 13 | $23,955 | $1,843 |
| Fulvestrant | None | 15 | $21,295 | $1,420 |
| Sancuso | None | 16 | $18,948 | $1,184 |
| Eliquis | None | 19 | $13,091 | $689 |
| Paclitaxel | None | 16 | $1,300 | $81 |
| Anastrozole | None | 65 | $1,035 | $16 |
| Hydroxyurea | None | 15 | $597 | $40 |
| Hydrocodone-Acetaminophen | None | 14 | $403 | $29 |
| Ondansetron | None | 30 | $335 | $11 |
| Letrozole | None | 12 | $325 | $27 |
2019: 30 drugs
| Procrit | None | 419 | $2,177,496 | $5,197 |
| Neulasta | None | 231 | $1,853,154 | $8,022 |
| Xtandi | None | 76 | $996,328 | $13,110 |
| Imbruvica | None | 49 | $722,120 | $14,737 |
| Zarxio | None | 44 | $651,365 | $14,804 |
| Ibrance | None | 49 | $585,205 | $11,943 |
| Ninlaro | None | 32 | $341,892 | $10,684 |
| Promacta | None | 20 | $332,451 | $16,623 |
| Revlimid | None | 17 | $272,306 | $16,018 |
| Xgeva | None | 106 | $241,923 | $2,282 |
| Jakafi | None | 18 | $227,440 | $12,636 |
| Imatinib Mesylate | None | 22 | $212,645 | $9,666 |
| Sprycel | None | 14 | $202,360 | $14,454 |
| Tecentriq | None | 22 | $199,452 | $9,066 |
| Gamunex-C | Immune globulin | 36 | $168,068 | $4,669 |
| Lupron Depot | None | 33 | $153,607 | $4,655 |
| Sylatron | None | 12 | $144,853 | $12,071 |
| Gammagard Liquid | Immune globulin | 25 | $137,250 | $5,490 |
| Keytruda | None | 12 | $119,226 | $9,936 |
| Octagam | Immune globulin | 21 | $109,570 | $5,218 |
| Azacitidine | None | 15 | $97,290 | $6,486 |
| Perjeta | None | 15 | $81,162 | $5,411 |
| Herceptin | None | 16 | $79,948 | $4,997 |
| Hizentra | Immune globulin | 13 | $77,247 | $5,942 |
| Faslodex | None | 32 | $60,926 | $1,904 |
| Eliquis | None | 33 | $17,345 | $526 |
| Anastrozole | None | 76 | $1,191 | $16 |
| Hydroxyurea | None | 15 | $877 | $58 |
| Hydrocodone-Acetaminophen | None | 15 | $325 | $22 |
| Ondansetron | None | 24 | $304 | $13 |
2018: 41 drugs
| Procrit | None | 393 | $2,202,570 | $5,605 |
| Neulasta | None | 241 | $1,742,576 | $7,231 |
| Imbruvica | None | 57 | $710,714 | $12,469 |
| Xtandi | None | 55 | $644,595 | $11,720 |
| Gammagard Liquid | Immune globulin | 94 | $542,465 | $5,771 |
| Ibrance | None | 46 | $529,573 | $11,512 |
| Neupogen | None | 31 | $486,164 | $15,683 |
| Zarxio | None | 32 | $347,294 | $10,853 |
| Sylatron | None | 26 | $318,009 | $12,231 |
| Revlimid | None | 15 | $233,901 | $15,593 |
| Keytruda | None | 24 | $221,233 | $9,218 |
| Ninlaro | None | 20 | $212,497 | $10,625 |
| Zejula | None | 12 | $188,063 | $15,672 |
| Xgeva | None | 75 | $169,226 | $2,256 |
| Sutent | None | 13 | $152,058 | $11,697 |
| Azacitidine | None | 23 | $143,021 | $6,218 |
| Lupron Depot | None | 32 | $139,206 | $4,350 |
| Zytiga | None | 13 | $131,993 | $10,153 |
| Gammagard S-D | Immune globulin | 15 | $102,312 | $6,821 |
| Perjeta | None | 17 | $90,112 | $5,301 |
| Tysabri | None | 14 | $89,628 | $6,402 |
| Herceptin | None | 17 | $84,049 | $4,944 |
| Faslodex | None | 32 | $63,863 | $1,996 |
| Nplate | None | 17 | $60,103 | $3,535 |
| Privigen | Immune globulin | 13 | $58,482 | $4,499 |
| Fondaparinux | None | 12 | $31,073 | $2,589 |
| Xarelto | None | 31 | $14,198 | $458 |
| Firmagon | None | 12 | $5,580 | $465 |
| Anastrozole | None | 122 | $2,554 | $21 |
| Hydroxyurea | None | 12 | $823 | $69 |
| Hydrocodone-Acetaminophen | None | 30 | $751 | $25 |
| Ondansetron | None | 37 | $739 | $20 |
| Tamoxifen Citrate | None | 16 | $537 | $34 |
| Dexamethasone | None | 14 | $448 | $32 |
| Megestrol Acetate | None | 12 | $341 | $28 |
| Venlafaxine Hcl Er | None | 18 | $338 | $19 |
| Bicalutamide | None | 11 | $260 | $24 |
| Lorazepam | None | 22 | $185 | $8 |
| Gabapentin | None | 14 | $134 | $10 |
| Zolpidem | None | 12 | $61 | $5 |
| Furosemide | None | 11 | $56 | $5 |
2017: 29 drugs
| Procrit | None | 292 | $1,480,261 | $5,069 |
| Neulasta | None | 184 | $1,327,314 | $7,214 |
| Gammagard Liquid | Immune globulin | 89 | $554,756 | $6,233 |
| Neupogen | None | 42 | $495,618 | $11,800 |
| Imbruvica | None | 37 | $414,896 | $11,213 |
| Sylatron | None | 20 | $216,710 | $10,836 |
| Zytiga | None | 23 | $212,852 | $9,254 |
| Tecentriq | None | 22 | $193,176 | $8,781 |
| Tysabri | None | 24 | $149,654 | $6,236 |
| Xtandi | None | 14 | $142,483 | $10,177 |
| Lonsurf | None | 12 | $135,682 | $11,307 |
| Ninlaro | None | 11 | $112,482 | $10,226 |
| Lupron Depot | None | 21 | $79,632 | $3,792 |
| Hizentra | Immune globulin | 13 | $71,635 | $5,510 |
| Azacitidine | None | 11 | $69,123 | $6,284 |
| Privigen | Immune globulin | 12 | $63,840 | $5,320 |
| Fondaparinux | None | 11 | $30,982 | $2,817 |
| Xarelto | None | 32 | $14,586 | $456 |
| Docetaxel | None | 16 | $3,366 | $210 |
| Anastrozole | None | 115 | $1,940 | $17 |
| Hydroxyurea | None | 35 | $1,300 | $37 |
| Tamoxifen Citrate | None | 36 | $976 | $27 |
| Ondansetron | None | 12 | $963 | $80 |
| Diphenhydramine | None | 11 | $819 | $74 |
| Ondansetron | None | 25 | $321 | $13 |
| Hydrocodone-Acetaminophen | None | 17 | $211 | $12 |
| Gabapentin | None | 12 | $128 | $11 |
| Prednisone | None | 11 | $88 | $8 |
| Omeprazole | None | 11 | $63 | $6 |
2016: 28 drugs
| Procrit | None | 221 | $1,016,079 | $4,598 |
| Neulasta | None | 78 | $683,423 | $8,762 |
| Gammagard Liquid | Immune globulin | 102 | $602,696 | $5,909 |
| Neupogen | None | 41 | $468,719 | $11,432 |
| Imbruvica | None | 46 | $466,382 | $10,139 |
| Zytiga | None | 37 | $314,910 | $8,511 |
| Revlimid | None | 13 | $149,563 | $11,505 |
| Sylatron | None | 15 | $142,128 | $9,475 |
| Azacitidine | None | 12 | $78,704 | $6,559 |
| Hizentra | Immune globulin | 14 | $77,146 | $5,510 |
| Tysabri | None | 13 | $75,225 | $5,787 |
| Lupron Depot | None | 18 | $63,374 | $3,521 |
| Fondaparinux | None | 11 | $29,470 | $2,679 |
| Xarelto | None | 33 | $12,575 | $381 |
| Exemestane | None | 11 | $6,168 | $561 |
| Dronabinol | None | 12 | $5,964 | $497 |
| Anastrozole | None | 116 | $1,449 | $12 |
| Hydroxyurea | None | 30 | $1,088 | $36 |
| Tamoxifen Citrate | None | 34 | $873 | $26 |
| Hydrocodone-Acetaminophen | None | 15 | $379 | $25 |
| Warfarin | None | 24 | $330 | $14 |
| Ondansetron | None | 12 | $254 | $21 |
| Dexamethasone | None | 11 | $216 | $20 |
| Venlafaxine Hcl Er | None | 18 | $206 | $11 |
| Gabapentin | None | 13 | $153 | $12 |
| Omeprazole | None | 24 | $124 | $5 |
| Prednisone | None | 23 | $116 | $5 |
| Furosemide | None | 14 | $74 | $5 |
2015: 25 drugs
| Procrit | None | 215 | $879,254 | $4,090 |
| Neulasta | None | 88 | $802,234 | $9,116 |
| Gammagard Liquid | Immune globulin | 109 | $619,243 | $5,681 |
| Neupogen | None | 34 | $429,084 | $12,620 |
| Zytiga | None | 32 | $252,934 | $7,904 |
| Sutent | None | 12 | $124,089 | $10,341 |
| Tysabri | None | 13 | $67,632 | $5,202 |
| Lupron Depot | None | 22 | $62,275 | $2,831 |
| Xgeva | None | 15 | $28,180 | $1,879 |
| Enoxaparin | None | 12 | $13,907 | $1,159 |
| Xarelto | None | 17 | $5,603 | $330 |
| Victoza 2-Pak | None | 12 | $5,563 | $464 |
| Hydrocodone-Acetaminophen | None | 42 | $1,618 | $39 |
| Tamoxifen Citrate | None | 43 | $1,422 | $33 |
| Raloxifene | None | 11 | $1,395 | $127 |
| Anastrozole | None | 71 | $1,137 | $16 |
| Hydroxyurea | None | 16 | $633 | $40 |
| Ondansetron | None | 29 | $619 | $21 |
| Warfarin | None | 45 | $544 | $12 |
| Gabapentin | None | 18 | $241 | $13 |
| Ondansetron | None | 13 | $223 | $17 |
| Prednisone | None | 22 | $160 | $7 |
| Megestrol Acetate | None | 11 | $151 | $14 |
| Venlafaxine Hcl Er | None | 13 | $105 | $8 |
| Lorazepam | None | 12 | $78 | $6 |
2014: 33 drugs
| Neupogen | None | 51 | $591,186 | $11,592 |
| Procrit | None | 173 | $585,682 | $3,385 |
| Neulasta | None | 54 | $458,259 | $8,486 |
| Revlimid | None | 20 | $189,903 | $9,495 |
| Gammagard Liquid | Immune globulin | 28 | $169,187 | $6,042 |
| Xtandi | None | 13 | $109,591 | $8,430 |
| Herceptin | None | 12 | $94,338 | $7,861 |
| Fondaparinux | None | 28 | $61,786 | $2,207 |
| Alimta | None | 11 | $35,507 | $3,228 |
| Docetaxel | None | 17 | $30,676 | $1,804 |
| Enoxaparin | None | 23 | $26,135 | $1,136 |
| Xgeva | None | 14 | $24,790 | $1,771 |
| Lupron Depot | None | 14 | $14,652 | $1,047 |
| Emend | None | 13 | $12,784 | $983 |
| Exemestane | None | 27 | $5,719 | $212 |
| Lidocaine | None | 12 | $2,588 | $216 |
| Evista | None | 12 | $2,440 | $203 |
| Anastrozole | None | 62 | $2,179 | $35 |
| Tamoxifen Citrate | None | 69 | $1,714 | $25 |
| Warfarin | None | 65 | $819 | $13 |
| Hydrocodone-Acetaminophen | None | 28 | $771 | $28 |
| Ondansetron | None | 27 | $593 | $22 |
| Hydroxyurea | None | 17 | $528 | $31 |
| Morphine Sulfate Er | None | 15 | $486 | $32 |
| Omeprazole | None | 17 | $252 | $15 |
| Levothyroxine | None | 16 | $248 | $15 |
| Dexamethasone | None | 15 | $228 | $15 |
| Zolpidem | None | 25 | $179 | $7 |
| Hydromorphone | None | 15 | $170 | $11 |
| Gabapentin | None | 15 | $160 | $11 |
| Fluoxetine | None | 17 | $126 | $7 |
| Spironolactone | None | 16 | $118 | $7 |
| Furosemide | None | 17 | $65 | $4 |
2013: 32 drugs
| Procrit | None | 127 | $390,214 | $3,073 |
| Neupogen | None | 35 | $276,232 | $7,892 |
| Herceptin | None | 22 | $215,079 | $9,776 |
| Gammagard Liquid | Immune globulin | 15 | $118,846 | $7,923 |
| Neulasta | None | 11 | $89,257 | $8,114 |
| Xtandi | None | 11 | $82,690 | $7,517 |
| Fondaparinux | None | 30 | $58,619 | $1,954 |
| Enoxaparin | None | 30 | $35,238 | $1,175 |
| Xgeva | None | 13 | $21,675 | $1,667 |
| Exemestane | None | 24 | $4,455 | $186 |
| Fentanyl | None | 25 | $4,449 | $178 |
| Evista | None | 23 | $4,140 | $180 |
| Anastrozole | None | 50 | $2,830 | $57 |
| Morphine Sulfate Er | None | 18 | $1,616 | $90 |
| Tamoxifen Citrate | None | 43 | $904 | $21 |
| Transderm-Scop | None | 11 | $692 | $63 |
| Ondansetron | None | 23 | $499 | $22 |
| Hydromorphone | None | 18 | $486 | $27 |
| Warfarin | None | 24 | $466 | $19 |
| Hydrocodone-Acetaminophen | None | 26 | $440 | $17 |
| Hydroxyurea | None | 12 | $375 | $31 |
| Venlafaxine Hcl Er | None | 12 | $284 | $24 |
| Levothyroxine | None | 33 | $264 | $8 |
| Fluoxetine | None | 25 | $219 | $9 |
| Gabapentin | None | 16 | $191 | $12 |
| Azithromycin | None | 14 | $149 | $11 |
| Donepezil | None | 11 | $145 | $13 |
| Zolpidem | None | 13 | $113 | $9 |
| Lisinopril | None | 18 | $89 | $5 |
| Amlodipine Besylate | None | 11 | $85 | $8 |
| Furosemide | None | 19 | $83 | $4 |
| Quetiapine | None | 12 | $81 | $7 |
Money from drug and device companies
$2,451 in 2025
| 2025 | 30 | 104 | None | $2,451 |
| 2024 | 28 | 102 | None | $2,611 |
| 2023 | 26 | 105 | None | $2,585 |
| 2022 | 24 | 47 | None | $1,535 |
| 2021 | 29 | 77 | None | $1,865 |
| 2020 | 28 | 77 | None | $1,650 |
| 2019 | 30 | 87 | None | $2,220 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kisqali | $343 | 14 payments
|
| Pfizer | Xtandi | $217 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $195 | 8 payments
|
| Genentech USA | Tecentriq | $178 | 7 payments
|
| Janssen Biotech | Tecvayli | $173 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $146 | 5 payments
|
See all 102 published payments
| Taiho Oncology | Meals · 2025-12-12 | Lonsurf | $29 |
| Novartis Pharmaceuticals | Meals · 2025-12-09 | Kisqali | $23 |
| Gilead Sciences | Meals · 2025-12-04 | Trodelvy | $21 |
| Alexion Pharmaceuticals | Meals · 2025-11-25 | Ultomiris | $27 |
| Janssen Biotech | Meals · 2025-11-20 | Erleada | $38 |
| Array Biopharma | Meals · 2025-11-20 | Lorbrena | $14 |
| Incyte | Meals · 2025-11-17 | Jakafi | $21 |
| Merck Sharp & Dohme | Meals · 2025-11-13 | Keytruda | $27 |
| Genentech USA | Meals · 2025-11-07 | Venclexta | $3 |
| Genentech USA | Meals · 2025-11-07 | Venclexta | $23 |
| Agios Pharmaceuticals | Meals · 2025-10-30 | Pyrukynd | $18 |
| Pfizer | Meals · 2025-10-27 | Xtandi | $24 |
| Gilead Sciences | Meals · 2025-10-15 | Trodelvy | $21 |
| Genentech USA | Meals · 2025-10-13 | Tecentriq | $31 |
| Pfizer | Meals · 2025-10-09 | Ibrance | $28 |
| GlaxoSmithKline | Meals · 2025-10-01 | Ojjaara | $28 |
| EMD Serono | Meals · 2025-09-30 | None | $41 |
| Novartis Pharmaceuticals | Meals · 2025-09-23 | Kisqali | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-18 | Opdualag | $17 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Pluvicto | $32 |
| Novartis Pharmaceuticals | Meals · 2025-09-16 | Pluvicto | $3 |
| Novartis Pharmaceuticals | Meals · 2025-09-08 | Pluvicto | $29 |
| Novartis Pharmaceuticals | Meals · 2025-09-03 | Fabhalta | $20 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | Kisqali | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-08-21 | Libtayo | $27 |
| Janssen Biotech | Meals · 2025-08-14 | Carvykti | $22 |
| Rigel Pharmaceuticals | Meals · 2025-08-12 | Tavalisse | $22 |
| Stemline Therapeutics | Meals · 2025-08-11 | Orserdu | $19 |
| Novartis Pharmaceuticals | Meals · 2025-08-06 | Fabhalta | $30 |
| Janssen Biotech | Meals · 2025-08-04 | Tecvayli | $17 |
| Novartis Pharmaceuticals | Meals · 2025-07-30 | Kisqali | $24 |
| Lilly USA | Meals · 2025-07-28 | Verzenio | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-16 | Opdualag | $25 |
| Astellas Pharma US | Meals · 2025-07-15 | Xtandi | $26 |
| Genentech USA | Meals · 2025-07-14 | Tecentriq | $33 |
| Gilead Sciences | Meals · 2025-07-11 | Trodelvy | $31 |
| Array Biopharma | Meals · 2025-07-09 | Lorbrena | $15 |
| Incyte | Meals · 2025-07-07 | Monjuvi | $28 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-30 | None | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-24 | Tagrisso | $25 |
| Pfizer | Meals · 2025-06-17 | Elrexfio | $15 |
| Pfizer | Meals · 2025-06-05 | Padcev | $16 |
| Octapharma USA | Meals · 2025-06-03 | Panzyga | $30 |
| Pfizer | Meals · 2025-05-29 | Elrexfio | $25 |
| Stemline Therapeutics | Meals · 2025-05-27 | Orserdu | $27 |
| Merck Sharp & Dohme | Meals · 2025-05-22 | Keytruda | $25 |
| Novartis Pharmaceuticals | Meals · 2025-05-21 | Fabhalta | $22 |
| Celgene | Meals · 2025-05-20 | Reblozyl | $19 |
| Incyte | Meals · 2025-05-19 | Jakafi | $26 |
| Merck Sharp & Dohme | Meals · 2025-05-14 | Keytruda | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-12 | Enhertu | $29 |
| Legend Biotech USA | Meals · 2025-05-05 | Carvykti | $20 |
| Daiichi Sankyo | Meals · 2025-05-01 | Enhertu | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-30 | Opdualag | $15 |
| Celgene | Meals · 2025-04-28 | Reblozyl | $26 |
| Celgene | Meals · 2025-04-28 | Reblozyl | $3 |
| Lilly USA | Meals · 2025-04-24 | Verzenio | $29 |
| Kite Pharma | Meals · 2025-04-23 | Yescarta | $22 |
| Novartis Pharmaceuticals | Meals · 2025-04-22 | Kisqali | $31 |
| Abbvie | Meals · 2025-04-18 | Elahere | $26 |
| Genentech USA | Meals · 2025-04-14 | Tecentriq | $27 |
| Janssen Biotech | Meals · 2025-04-10 | Tecvayli | $19 |
| Array Biopharma | Meals · 2025-04-09 | Xalkori | $18 |
| Celgene | Meals · 2025-04-08 | Opdualag | $21 |
| Incyte | Meals · 2025-04-07 | Jakafi | $24 |
| Pfizer | Meals · 2025-04-04 | Xtandi | $26 |
| Astellas Pharma US | Meals · 2025-03-29 | Xtandi | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-27 | Opdualag | $25 |
| Merck Sharp & Dohme | Meals · 2025-03-27 | Keytruda | $25 |
| Merck Sharp & Dohme | Meals · 2025-03-26 | Keytruda | $35 |
| Sobi | Meals · 2025-03-25 | Vonjo | $16 |
| Stemline Therapeutics | Meals · 2025-03-24 | Elzonris | $17 |
| Celgene | Meals · 2025-03-20 | Opdualag | $31 |
| Janssen Biotech | Meals · 2025-03-13 | Tecvayli | $31 |
| Astellas Pharma US | Meals · 2025-03-10 | Xtandi | $20 |
| Incyte | Meals · 2025-03-06 | Jakafi | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-04 | Calquence | $29 |
| Gilead Sciences | Meals · 2025-03-03 | Trodelvy | $33 |
| Genentech USA | Meals · 2025-02-26 | Venclexta | $32 |
| Pfizer | Meals · 2025-02-25 | Bosulif | $20 |
| Sobi | Meals · 2025-02-24 | Vonjo | $15 |
| Novartis Pharmaceuticals | Meals · 2025-02-20 | Kisqali | $24 |
| Novartis Pharmaceuticals | Meals · 2025-02-19 | Fabhalta | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-17 | Tagrisso | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-13 | Enhertu | $25 |
| Pfizer | Meals · 2025-02-13 | Tivdak | $36 |
| Azurity Pharmaceuticals | Meals · 2025-02-11 | Danziten | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-06 | Imfinzi | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-06 | Imfinzi | $8 |
| Pfizer | Meals · 2025-02-05 | Xtandi | $27 |
| Eisai | Meals · 2025-02-04 | Lenvima | $15 |
| Legend Biotech USA | Meals · 2025-02-03 | Carvykti | $26 |
| Celgene | Meals · 2025-01-30 | Opdualag | $20 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-27 | Opdualag | $25 |
| Janssen Biotech | Meals · 2025-01-23 | Tecvayli | $27 |
| Novartis Pharmaceuticals | Meals · 2025-01-21 | Kisqali | $28 |
| Celgene | Meals · 2025-01-15 | Reblozyl | $21 |
| Janssen Biotech | Meals · 2025-01-14 | Erleada | $18 |
| Incyte | Meals · 2025-01-13 | Jakafi | $17 |
| Astellas Pharma US | Meals · 2025-01-10 | Xtandi | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-07 | Calquence | $26 |
| Genentech USA | Meals · 2025-01-06 | Tecentriq | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,611
| Novartis Pharmaceuticals | Kisqali | $461 | 8 payments
|
| Pfizer | Elrexfio | $329 | 18 payments
|
| Amgen | Kyprolis | $239 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $211 | 6 payments
|
| Daiichi Sankyo | Enhertu | $153 | 7 payments
|
| Gilead Sciences | Trodelvy | $149 | 11 payments
|
| Genentech USA | Tecentriq | $117 | 4 payments
|
| Incyte | Jakafi | $97 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdualag | $81 | 4 payments
|
| Astellas Pharma US | Xtandi | $77 | 3 payments
|
| Janssen Biotech | Darzalex | $74 | 3 payments
|
| Abbvie | Venclexta | $62 | 3 payments
|
| Agios Pharmaceuticals | Pyrukynd | $54 | 2 payments
|
| Eisai | Lenvima | $51 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $50 | 2 payments
|
| PharmaEssentia USA | Besremi | $50 | 2 payments
|
| Array Biopharma | Xalkori | $49 | 3 payments
|
| Adaptive Biotechnologies | Clonoseq | $45 | 2 payments
|
| Lilly USA | Verzenio | $42 | 2 payments
|
| Celgene | Reblozyl | $35 | 2 payments
|
| EMD Serono | None | $35 | 1 payment
|
| Puma Biotechnology | None | $28 | 1 payment
|
| Mirati Therapeutics | Krazati | $23 | 1 payment
|
| Novocure | Optune Lua (Novottf-200t) | $22 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $21 | 1 payment
|
| Azurity Pharmaceuticals | Vivimusta | $20 | 1 payment
|
| Octapharma USA | Panzyga | $18 | 1 payment
|
| Legend Biotech USA | None | $17 | 1 payment
|
2023: $2,585
| Novartis Pharmaceuticals | Kisqali | $373 | 6 payments
|
| Janssen Biotech | Tecvayli | $275 | 9 payments
|
| Merck Sharp & Dohme | Keytruda | $224 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $179 | 9 payments
|
| Incyte | Jakafi | $166 | 7 payments
|
| Pfizer | Ibrance | $159 | 9 payments
|
| EMD Serono | Tepmetko | $138 | 5 payments
|
| Seagen | Adcetris | $129 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $98 | 5 payments
|
| Genzyme | Sarclisa | $97 | 4 payments
|
| Genentech USA | Tecentriq | $85 | 3 payments
|
| Amgen | Blincyto | $77 | 4 payments
|
| Astellas Pharma US | Xtandi | $74 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $67 | 3 payments
|
| Gilead Sciences | Trodelvy | $64 | 3 payments
|
| Eisai | Lenvima | $54 | 3 payments
|
| Mirati Therapeutics | Krazati | $52 | 3 payments
|
| Lilly USA | Verzenio | $51 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $48 | 2 payments
|
| Cardinal Health 108 | None | $43 | 2 payments
|
| GlaxoSmithKline | Ojjaara | $28 | 1 payment
|
| PharmaEssentia USA | Besremi | $28 | 1 payment
|
| Celgene | Pomalyst | $24 | 1 payment
|
| Foundation Medicine | None | $21 | 1 payment
|
| Puma Biotechnology | None | $17 | 1 payment
|
| Tolmar | Eligard | $15 | 1 payment
|
2022: $1,535
| Novartis Pharmaceuticals | Kisqali | $199 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $183 | 4 payments
|
| Janssen Biotech | Darzalex | $170 | 4 payments
|
| Amgen | Kyprolis | $154 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $152 | 2 payments
|
| ADC Therapeutics America | None | $138 | 7 payments
|
| Pfizer | Inlyta | $69 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $47 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $44 | 2 payments
|
| Celgene | Reblozyl | $41 | 2 payments
|
| Astellas Pharma US | Xospata | $39 | 2 payments
|
| Daiichi Sankyo | Enhertu | $33 | 2 payments
|
| GE HealthCare | None | $29 | 1 payment
|
| Genentech USA | Tecentriq | $27 | 1 payment
|
| Seagen | Adcetris | $27 | 1 payment
|
| Kite Pharma | None | $27 | 1 payment
|
| Lilly USA | Verzenio | $27 | 1 payment
|
| Cardinal Health 108 | None | $21 | 1 payment
|
| ViiV Healthcare | Apretude | $21 | 1 payment
|
| Incyte | Jakafi | $20 | 1 payment
|
| Gilead Sciences | Trodelvy | $19 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $19 | 1 payment
|
| Genzyme | Sarclisa | $16 | 1 payment
|
| Abbvie | Lupron Depot | $13 | 1 payment
|
2021: $1,865
| Genzyme | Libtayo | $263 | 8 payments
|
| Pfizer | Inlyta | $220 | 10 payments
|
| Merck Sharp & Dohme | Keytruda | $129 | 7 payments
|
| Amgen | Nplate | $118 | 4 payments
|
| GlaxoSmithKline | Zejula | $110 | 4 payments
|
| Lilly USA | Cyramza | $103 | 5 payments
|
| Alexion Pharmaceuticals | Ultomiris | $90 | 2 payments
|
| Kite Pharma | None | $72 | 3 payments
|
| Janssen Biotech | Erleada | $69 | 3 payments
|
| Seagen | Adcetris | $61 | 3 payments
|
| Puma Biotechnology | Nerlynx | $61 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $60 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $53 | 3 payments
|
| Incyte | Jakafi | $50 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $49 | 2 payments
|
| Astellas Pharma US | Xospata | $44 | 2 payments
|
| Celgene | Reblozyl | $42 | 2 payments
|
| Octapharma USA | Octagam Immune Globulin (Human) | $34 | 1 payment
|
| Ge Healthcare | None | $30 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $26 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $23 | 1 payment
|
| Eisai | Lenvima | $22 | 1 payment
|
| Daiichi Sankyo | Enhertu | $21 | 1 payment
|
| Epizyme | Tazverik | $21 | 1 payment
|
| ADC Therapeutics America | None | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $20 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $20 | 1 payment
|
| Secura Bio | Farydak | $19 | 1 payment
|
| Gilead Sciences | Trodelvy | $15 | 1 payment
|
2020: $1,650
| BeiGene USA | Brukinsa | $184 | 10 payments
|
| Merck Sharp & Dohme | Keytruda | $172 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $160 | 4 payments
|
| GlaxoSmithKline | Zejula | $133 | 6 payments
|
| Janssen Biotech | Erleada | $81 | 4 payments
|
| Genzyme | Sarclisa | $72 | 4 payments
|
| Incyte | Jakafi | $70 | 3 payments
|
| Amgen | Kyprolis | $63 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $63 | 3 payments
|
| Alexion Pharmaceuticals | Soliris | $63 | 2 payments
|
| Pfizer | Bavencio | $59 | 3 payments
|
| Seagen | Adcetris | $59 | 3 payments
|
| Octapharma USA | Octagam Immune Globulin (Human) | $52 | 2 payments
|
| Daiichi Sankyo | Enhertu | $50 | 3 payments
|
| Blueprint Medicines | Gavreto | $44 | 2 payments
|
| Eisai | Lenvima | $44 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $40 | 2 payments
|
| Kite Pharma | None | $31 | 1 payment
|
| Tactile Systems Technology | Flexitouch | $28 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $28 | 2 payments
|
| CSL Behring | Idelvion | $25 | 1 payment
|
| Lilly USA | Alimta | $23 | 1 payment
|
| Celgene | Onureg | $21 | 1 payment
|
| AbbVie | Lupron Depot | $19 | 1 payment
|
| Epizyme | Tazverik | $19 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $18 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $17 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $12 | 1 payment
|
2019: $2,220
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $384 | 5 payments
|
| Genentech USA | Alecensa | $209 | 5 payments
|
| Tesaro | Zejula | $168 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $164 | 12 payments
|
| Janssen Pharmaceuticals | Xarelto | $138 | 2 payments
|
| Array BioPharma | Braftovi | $133 | 9 payments
|
| Portola Pharmaceuticals | Andexxa | $122 | 1 payment
|
| Genzyme | Cablivi | $93 | 5 payments
|
| Amgen | Kyprolis | $85 | 4 payments
|
| Rigel Pharmaceuticals | Tavalisse | $79 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $71 | 4 payments
|
| Astellas Pharma US | Xtandi | $70 | 3 payments
|
| Novartis Pharmaceuticals | Mekinist | $56 | 3 payments
|
| Puma Biotechnology | Nerlynx | $52 | 3 payments
|
| Seattle Genetics | Adcetris | $51 | 3 payments
|
| Janssen Biotech | Darzalex | $45 | 2 payments
|
| Pfizer | Ibrance | $44 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $36 | 2 payments
|
| Celgene | Revlimid | $36 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $26 | 1 payment
|
| Gilead Sciences | None | $19 | 1 payment
|
| Lilly USA | Cyramza | $18 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Akynzeo | $18 | 1 payment
|
| EMD Serono | Bavencio | $17 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $17 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $16 | 1 payment
|
| Octapharma USA | Octagam Immune Globulin (Human) | $16 | 1 payment
|
| Eisai | Lenvima | $14 | 1 payment
|
| Incyte | Jakafi | $12 | 1 payment
|
| Clovis Oncology | Rubraca | $9 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1619933132
- Licence
- CA A86460California A86460: Current · expires 2028-01-31
- Trained
- Tulane University School of Medicine, 1998 · 28 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A864600, CA GR0044500, CA GR0044501, CA ZZZ70294Z
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 7325 Medical Center Dr Ste 301, West Hills, CA, 91307
- NPI first listed
- 2006-04-24
- NPI last updated
- 2023-01-24
- NPI record certified
- 2023-01-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 10630 Sepulveda Blvd # 202, Mission Hills, CA, 91345 · 3605 Alamo St Ste 103, Simi Valley, CA, 93063